サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1675350

非アルコール性脂肪性肝炎（NASH）市場：薬剤タイプ別、疾患原因別、販売チャネル別、エンドユーザー別、地域別、2025-2033年

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 142 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
非アルコール性脂肪性肝炎（NASH）市場：薬剤タイプ別、疾患原因別、販売チャネル別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非アルコール性脂肪性肝炎（NASH）市場規模は2024年に19億米ドルに達しました。今後、IMARC Groupは、2033年までに同市場が135億米ドルに達し、2025～2033年の成長率（CAGR）は22.97％に達すると予測しています。NASHの有病率の上昇、早期診断と治療に関する意識の高まり、人工知能（AI）と機械学習（ML）技術の統合は、市場を牽引する主な要因のいくつかを表しています。

非アルコール性脂肪性肝炎（NASH）は、インスリン抵抗性、過体重、メタボリックシンドロームによって引き起こされる進行性の非アルコール性脂肪肝疾患（NAFLD）を指します。その症状は、疲労感や脱力感、体重減少、黄疸、皮膚のかゆみ、クモ状静脈、肝臓肥大、集中力の欠如、体液貯留、痛みや腫れなどの腹部不快感を伴う。健康診断、血液検査、肝生検、磁気共鳴画像法（MRI）、超音波検査、コンピューター断層撮影法（CT）など、複数の検査法によって診断されます。NASHの治療には、薬物療法、肝移植、定期的な運動や健康的な食事などの様々な生活習慣の改善が含まれます。これらの治療法は、肝脂肪の蓄積を抑え、肝機能を改善し、炎症を抑え、肝障害を最小限に抑えるのに役立ちます。また、患者の生活の質を高め、長期的な転帰を改善し、肥満や高血圧などの他の健康問題をよりよく管理することができます。

非アルコール性脂肪性肝炎（NASH）市場の動向：

遺伝、座りがちなライフスタイル、不健康な食習慣、肥満、2型糖尿病などによるNASHの有病率の上昇は、市場成長を促進する主な要因の1つです。これに伴い、NASH治療は症状の緩和、寿命の延長、早死の防止、肝臓の健康増進、全体的な健康増進を目的として患者に広く採用されており、これが市場成長の推進力となっています。さらに、医療費を削減し、肝移植の必要性をなくし、高血圧、心血管疾患（CVDs）、がん、肝硬変、肝不全などの将来の合併症を予防するために、NASHの早期診断と治療に関する大衆の意識が高まっていることが、市場成長の原動力となっています。さらに、MRIや一過性エラストグラフィ（TE）などの非侵襲的画像診断技術をNASHのモニタリングや診断に活用することで、患者の快適性を高め、コンプライアンスを向上させ、合併症のリスクを低減し、臨床転帰を改善することが、市場成長にプラスの影響を与えています。これに加えて、個別化治療の開発、診断精度の向上、市場開拓予測のための人工知能（AI）と機械学習（ML）の統合が市場成長に好影響を与えています。さらに、質の高い治療へのアクセスを提供し、先進的な治療薬の市場開拓を支援するためのさまざまな政府イニシアチブの実施が、市場の成長を促進しています。その他、高齢者人口の増加、医療費の増加、広範な研究開発（R&D）活動、医療業界の著しい成長、非侵襲的な治療オプションに対する需要の増加などが、市場成長の原動力になると予測されます。

本レポートで扱う主な質問

  • 世界の非アルコール性脂肪性肝炎（NASH）市場の規模は？
  • 2025-2033年における世界の非アルコール性脂肪性肝炎（NASH）市場の予想成長率は？
  • 世界の非アルコール性脂肪性肝炎（NASH）市場を牽引する主要因は？
  • COVID-19が世界の非アルコール性脂肪性肝炎（NASH）市場に与えた影響は？
  • 非アルコール性脂肪性肝炎（NASH）の世界市場における薬剤タイプ別の区分は？
  • 疾患原因に基づく非アルコール性脂肪性肝炎（NASH）の世界市場内訳は？
  • 販売チャネルに基づく非アルコール性脂肪性肝炎（NASH）の世界市場内訳は？
  • エンドユーザーに基づく非アルコール性脂肪性肝炎（NASH）の世界市場内訳は？
  • 世界の非アルコール性脂肪性肝炎（NASH）市場における主要地域は？
  • 世界の非アルコール性脂肪性肝炎（NASH）市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の非アルコール性脂肪性肝炎（NASH）市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • ビタミンE・ピオグリタゾン
  • オカリバ
  • エラフィブラノール
  • セロンセルチブ
  • セニクリビロック
  • その他

第7章 市場内訳：疾患原因別

  • 高血圧
  • 心臓病
  • 高血中脂質
  • 2型糖尿病
  • 肥満

第8章 市場内訳：販売チャネル別

  • 病院薬局
  • オンラインプロバイダー
  • 小売薬局

第9章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • 在宅医療

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第11章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited
図表

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2024
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2024
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2024
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million USD), 2025-2033
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million USD), 2025-2033
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players
目次
Product Code: SR112025A7397

The global non-alcoholic steatohepatitis (NASH) market size reached USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.5 Billion by 2033, exhibiting a growth rate (CAGR) of 22.97% during 2025-2033. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

Key Market Segmentation:

Drug Type Insights:

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

Disease Cause Insights:

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity

Sales Channel Insights:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Homecare Settings

Regional Insights:

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1.How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 2.What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2025-2033?
  • 3.What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 4.What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 5.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
  • 6.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
  • 7.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
  • 8.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
  • 9.What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 10.Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.